Skip to Content

Consolidation Treatment with VRD improves PFS and deep response in Newly Diagnosed Patients with Multiple Myeloma

In this MEDtalk, the world-leading expert in multiple myeloma, Professor Pieter Sonneveld, presents the result of the final analysis phase 3 trial of the European Myeloma Network of VRD consolidation therapy followed by lenalidomide in patients with Newly Diagnosed Multiple Myeloma. The study shows that VRD consolidation therapy followed by lenalidomide improves PFS and depth of response.

Pieter Sonneveld

Lue artikkeli

Jos olet lääkäri, farmaseutti tai rajatun lääkkeenmääräämisoikeuden omaava sairaanhoitaja, pääset lukemaan artikkelin kirjautumalla käyttäjäksi BestPractice Nordic -sivustolle.

Back to top